OGI vs. WEED, CMED, EMC, ICC, LEAF, MGW, BE, BLO, SL, and MJN
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Canopy Growth (WEED), CanniMed Therapeutics (CMED), Emblem (EMC), ICC Labs (ICC), Leaf Mobile (LEAF), Maple Leaf Green World (MGW), Beleave (BE), Cannabix Technologies (BLO), Supreme Cannabis Company Inc, (SL), and Cronos Group (MJN). These companies are all part of the "cannabis" industry.
Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
Canopy Growth received 593 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.38% of users gave Canopy Growth an outperform vote while only 44.34% of users gave Organigram an outperform vote.
Canopy Growth has a net margin of 0.00% compared to Canopy Growth's net margin of -153.80%. Canopy Growth's return on equity of -54.53% beat Organigram's return on equity.
Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
14.0% of Canopy Growth shares are held by institutional investors. Comparatively, 12.2% of Organigram shares are held by institutional investors. 0.3% of Canopy Growth shares are held by company insiders. Comparatively, 27.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Canopy Growth had 3 more articles in the media than Organigram. MarketBeat recorded 9 mentions for Canopy Growth and 6 mentions for Organigram. Canopy Growth's average media sentiment score of 0.58 beat Organigram's score of 0.56 indicating that Organigram is being referred to more favorably in the news media.
Canopy Growth currently has a consensus target price of C$3.78, suggesting a potential downside of 67.36%. Organigram has a consensus target price of C$3.76, suggesting a potential upside of 60.61%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than Canopy Growth.
Canopy Growth has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
Summary
Canopy Growth and Organigram tied by winning 9 of the 18 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Organigram Competitors List
Related Companies and Tools